Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrated Stress Response (ISR) Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF2A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF2A Recombinant Protein (Wild-Type & Mutants) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for kinase assays. |
View EIF2A Products |
| Gene Delivery | EIF2A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View EIF2A Products |
| Benchmark Ab | Anti-EIF2A Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and IP. |
View EIF2A Products |
| Validator | EIF2A siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View EIF2A Products |
| Related Target A | EIF2AK3 (PERK) Upstream kinase phosphorylating EIF2A under endoplasmic reticulum (ER) stress. |
View EIF2AK3 Products |
| Related Target B | EIF2AK4 (GCN2) Upstream kinase regulating EIF2A phosphorylation in response to amino acid deprivation. |
View EIF2AK4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phosphorylation-state specificity validation | Recombinant EIF2A mutant proteins (e.g., S51A, S51D) sequence verified for phosphorylation-null and phosphomimetic assay controls. |
| Upstream kinase selectivity screening | Comprehensive panel of highly active recombinant kinases (PERK, GCN2, PKR, HRI) with >90% purity. |
| Lack of reliable assay controls | Sequence-derived recombinant benchmark antibodies included for assay standardization. |
| Target-specific off-target validation | Validated siRNA sets included to confirm phenotype specificity in cellular models. |
Live EIF2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF2A pathway therapeutics is intensifying, with major players shifting focus from traditional global translation inhibition to precise modulation of the Integrated Stress Response (ISR). As first-generation small molecule inhibitors and activators reach the clinic, the next wave of R&D is targeting neurodegenerative disorders, oncology, and metabolic diseases through highly selective allosteric modulators of the eIF2 complex and its upstream kinases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (eIF2B Activators/ISRIB) | Calico Life Sciences, AbbVie, Denali Therapeutics | ALS, Vanishing White Matter Disease, TBI | In vitro binding assays (Need highly stable WT and mutant EIF2A complexes) |
| Small Molecule (PERK/GCN2 Inhibitors) | Roche, AstraZeneca, GSK | Solid Tumors, Neurodegeneration | Kinase profiling panels (Need active kinase domains and EIF2A substrates) |
| Gene Therapy / RNAi | Academic Consortia, Biotech Startups | Rare Genetic Neuropathies | Target knockdown validation (Need sequence-verified siRNA and Lentivirus) |